MRNAModerna, Inc.

Nasdaq modernatx.com


$ 133.39 $ -1.00 (-0.74 %)    

Friday, 21-Jun-2024 15:59:55 EDT
QQQ $ 480.84 $ -1.29 (-0.27 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 133.4
$ 135.37
$ 0.00 x 0
$ 0.00 x 0
$ 132.30 - $ 136.29
$ 62.55 - $ 170.47
5,225,264
na
50.96B
$ 0.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 10-30-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

 openai-and-color-health-develop-ai-driven-cancer-care-solutions-report

OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating pers...

Core News & Articles

- Reuters

 moderna-says-higher-efficacy-was-observed-in-mrna-1283-compared-to-spikevax-in-adults-18-years-of-age-and-older

"We are very pleased that mRNA-1283 has now met its primary vaccine efficacy endpoint in Phase 3, and showed higher efficac...

 oppenheimer-maintains-outperform-on-moderna-raises-price-target-to-179

Oppenheimer analyst Hartaj Singh maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $163 to ...

Core News & Articles

- Reuters Citing Goldman Sachs Conference

 whats-going-on-with-moderna-stock-monday

Moderna said its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, met its pri...

 nike-merck-general-motors-and-more-cnbcs-final-trades

Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of ...

 moderna-seeks-fda-approval-for-updated-covid-19-shot-for-upcoming-season

Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.

Core News & Articles

- Reuters

 moderna-submits-application-to-fda-for-review-of-spikevax-2024-2025-formula-targeting-sars-cov-2-variant-jn1

https://www.accesswire.com/872882/moderna-initiates-submission-to-fda-of-jn1-targeting-covid-19-vaccine

 first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map

Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.

 fda-selects-modernas-rare-disease-candidate-for-accelerated-development-program

Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2...

Core News & Articles

- Bloomberg